Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after the drug failed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE